Herwenda

Herwenda is a prescription intravenous solution that contains the monoclonal antibody trastuzumab as its active ingredient. It is supplied in a standard concentration for infusion and is marketed in the European Union. Trastuzumab belongs to the HER2 receptor antagonist class and is used under physician guidance to target cancers that overexpress the HER2 protein. The product is administered by a healthcare professional in a clinical setting.

Herwenda is indicated for the treatment of several HER2‑positive malignancies, both in advanced and early disease stages, under physician guidance.

- HER2‑positive metastatic breast cancer, typically in combination with chemotherapy. - HER2‑positive early‑stage breast cancer as adjuvant therapy after surgery. - HER2‑positive gastric adenocarcinoma, often with a fluoropyrimidine‑based regimen. - HER2‑positive gastro‑esophageal junction adenocarcinoma in the metastatic setting. - HER2‑positive breast cancer with brain metastases when systemic control is needed.

Adverse reactions to Herwenda have been observed in clinical practice; they range from mild, frequently reported events to rare but serious conditions.

Common: - Fever, chills, or flu‑like symptoms that may appear during or shortly after the infusion. - Nausea, vomiting, or loss of appetite, often mild and manageable with supportive care. - Fatigue or generalized weakness that can persist for several days post‑treatment.

Serious: - Cardiac dysfunction, including a measurable reduction in left ventricular ejection fraction that may require cardiac monitoring. - Severe allergic reactions (anaphylaxis) presenting with respiratory distress, urticaria, or hypotension. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention.

Herwenda should be used only after a thorough clinical assessment, and several precautions are recommended to minimize risk. - Baseline and periodic cardiac evaluation (e.g., echocardiogram) is advised for patients with existing heart disease. - Infusion should be administered in a setting equipped for emergency management of hypersensitivity reactions. - Patients with known hypersensitivity to trastuzumab or any component of the formulation should not receive Herwenda. - Caution is warranted in individuals with impaired hepatic function, as metabolism may be altered. - Monitor complete blood counts regularly to detect neutropenia or thrombocytopenia. - Avoid concurrent use with live vaccines due to potential immune modulation.

Herwenda may interact with other agents; awareness of potential pharmacodynamic and pharmacokinetic interactions helps ensure safe co‑administration.

Avoid: - Concurrent use with other HER2‑targeted monoclonal antibodies (e.g., pertuzumab) without specialist guidance, due to overlapping toxicity. - Live attenuated vaccines during treatment, because immune response may be compromised. - Concurrent use with other monoclonal antibodies targeting EGFR may increase risk of skin toxicity.

Use with caution: - Anthracycline chemotherapy (e.g., doxorubicin) because of additive cardiac risk. - Concomitant cardiotoxic agents such as trastuzumab‑deruxtecan or certain tyrosine kinase inhibitors. - Medications that prolong QT interval, as trastuzumab may rarely affect cardiac repolarization. - Corticosteroids may mask early signs of infusion reactions; monitor patients closely.